Skip to main content

Retail Clinics

  • UltiMed introduces 50-count needles offering for diabetes patients

    ST. PAUL, Minn. — UltiMed is offering 50-count pen needles for patients with diabetes, the company announced.

    The company said the needles would give diabetes patients a high-quality and cost-effective option for their pen needle supplies. Before, pen needles were dispensed in quantities of 100.

    UltiMed said its needles, manufactured in its De Smet, S.D., factory, are the only ones assembled in the United States.

  • HealthOneMed debuts Dispense-a-Pill

    LEHIGH VALLEY, Pa. — HealthOneMed has launched a device that combines the abilities of pillboxes, reminders, dispensers and medication alerts into one.

  • Wellesse introduces digestive health supplement

    FERNDALE, Wash. — Wellesse earlier this week introduced its Digestive 3-in-1 Health, a liquid supplement that promotes healthy digestion and regularity, soothes the stomach and helps the body resist occasional imbalance.

    "Most people who indulge pay for it with uncomfortable, embarrassing or even tiring digestive symptoms on a regular basis," stated registered dietitian Marie Spano, speaking on behalf of Wellesse.

  • Oral contraceptive Emoquette wins FDA approval

    HUNTSVILLE, Ala. — A subsidiary of Endo Pharmaceuticals has won approval from the Food and Drug Administration for an oral contraceptive.

    Qualitest Pharmaceuticals announced Friday the approval of Emoquette (desogestrel and ethinyl estradiol) tablets in the 0.15-mg/0.03-mg strength.

    The drug is a generic version of Johnson & Johnson’s Ortho-Cept.

  • Manhattan Institute studies state of clinics

    NEW YORK — The Manhattan Institute has come up with a novel idea to help New York state slash its healthcare costs by a hefty $350 million by 2020: Expand access to retail health clinics.

    Sounds simple enough, right? Think again.

  • FDA lifts liver injury risk boxed warning from Gilead's Letairis

    FOSTER CITY, Calif. — Gilead on Friday announced that the Food and Drug Administration has removed a boxed warning about a possible liver injury risk caused by the drug maker's hypertension treatment.

    Gilead said the FDA approved a change to the prescribing information for Letairis (ambrisentan 5-mg and 10-mg tablets), the company’s once-daily treatment of pulmonary arterial hypertension.

  • Vaccine push hits retail

    With pharmacists across the country now able to administer vaccinations, the Department of Health and Human Services’ plan came at just the right time.

  • NSAIDs could pose erectile dysfunction risk among men

    PASADENA, Calif. — Long-term use of a class of drugs used to control pain could increase the risk of erectile dysfunction in men, according to a new study.

    The study, sponsored by Kaiser Permanente and published online in the Journal of Urology, found that men who took nonsteroidal anti-inflammatory drugs, or NSAIDs, three times a day for more than three months were 2.4 times as likely to have erectile dysfunction as men who didn’t take the drugs regularly. The study used data from 80,966 men ages 45 to 69 years in California.

X
This ad will auto-close in 10 seconds